Select Your Region
LACTEL® 50:50 DL-PLGE, IV 0.15-0.25 is a biodegradable PLGA-based copolymer made up of a 50:50 ratio of D,L-lactide and glycolide with an inherent viscosity of 0.15─0.25 dL/g in HFIP. LACTEL® 50:50 DL-PLGE, IV 0.15-0.25 is non-GMO certified and contains no added preservatives for pharmaceautical and medical applications. LACTEL® 50:50 DL-PLGE, IV 0.15-0.25 offers a degredation period of 3 months.
Physical state: Solid
Form: Granules
Color: White to light tan
Inherent viscosity (IV) dL/g: 0.15─0.25 (in HFIP)
Degradation time: <3 months
Density (g/mL): 1.34
Tensile Strength (psi): 6000─8000
Elongation (%): 3─10
Modulus (psi): 2─4x10⁵
CAS No. 26780-50-7
Primary Chemistry:
Poly(DL-lactide-co-glycolide)
LACTEL® 50:50 DL-PLGE, IV 0.15-0.25 is a functional excipient from Evonik recommended for parenteral controlled release systems, long acting injectable formulations, and human generic drug formulations. Manufactured using a streamlined process to produce a PLGA copolymer containing 50% Glycolide and 50% D,L-lactide, LACTEL® 50:50 DL-PLGE, IV 0.15-0.25 offers a cost effective solution for the formulating of high-quality pharmaceutical products that meet market demands. It is compatible with various substances, including proteins, peptides, nanoparticles, and microparticles, and is 100% bioabsorbable for complete metabolization in the body.
Physical state: Solid
Form: Granules
Color: White to light tan
Inherent viscosity (IV) dL/g: 0.15─0.25 (in HFIP)
Degradation time: <3 months
Density (g/mL): 1.34
Tensile Strength (psi): 6000─8000
Elongation (%): 3─10
Modulus (psi): 2─4x10⁵
CAS No. 26780-50-7
Primary Chemistry:
Poly(DL-lactide-co-glycolide)
Human generic drug formulations
Long-acting injectable formulations
Price sensitive applications
veterinary medicine
We’ve detected that you are located in a different region than the region selected on the website. Would you like to change your region?
Current Region: English - United States